AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04538313
Drug: Tumor infiltrating lymphocyte
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: CD8+ enriched young tumor infiltrating lymphocytes (DB17460)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor infiltrating lymphocytes were isolated from tumor tissues from tumor biopsy or operation. These TILs were cultured in human IL-2 medium for 4 to 5 weeks. 10e9 to 10e10 TILs were yielded. The phenotype, function and sterile were detected before these TILs infused patients.
Trial: NCT01007461
Drug: Sodium Sulfide (Na2S) for Injection
RxNorm normalized name: Sodium Sulfide
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IK-1001 is Na2S administered as an isotonic solution for intravenous (IV) injection or continuous infusion. IK-1001 will be administered as a 3-hour continuous IV infusion started \> 5 minutes but \< 20 minutes (approximately) prior to coronary artery reperfusion.
Trial: NCT03731260
Drug: Avapritinib
RxNorm normalized name: Avapritinib
DrugBank: Avapritinib (DB15233)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Avapritinib tablet
Trial: NCT01731067
Drug: Cocktail probe drugs
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03852979
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: weekly paclitaxel 80 mg/m2 for 12 weeks
Trial: NCT01195467
Drug: Truvada/Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All subjects currently on Atripla® will switch to Truvada/Raltegravir
Trial: NCT01523483
Drug: Progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two micronized progesterone capsules (Utrogestan® 200 mg, i.e. 400 mg of micronized progesterone in sunflower oil) placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
Trial: NCT03852979
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: weekly carboplatin AUC=2 for 12 weeks
Trial: NCT02293785
Drug: Oxycodone-Naloxone
RxNorm normalized name: naloxone / oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01940536
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antifibrinolytic
Trial: NCT03913143
Drug: sepofarsen
RxNorm normalized name: Sepofarsen
DrugBank: Sepofarsen (DB16327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RNA antisense oligonucleotide for intravitreal injection
Trial: NCT00490776
Drug: Panobinostat
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panobinostat, 20 mg, hard gelatin capsules, orally, thrice weekly.
Trial: NCT00086099
Drug: Idarubincin and Amufostine (Ethyol)
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Starting doses of Idarubincin(12,18 mg/m2 to 21 mg/m2), ara-C, plus amofostine (N-36)
Trial: NCT04401878
Drug: Sphenopalatine Ganglion Block using 2% lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sphenopalatine Ganglion Block is performed by a hollow culture swab that is connected with a 21-gauge syringe filled with three ml 2% lidocaine, inserted parallel to the floor of the nose until resistance is felt. The swab is at the posterior pharyngeal wall superior to the middle turbinate. The applicator was kept in the nostril for five to ten mins. The same procedure is done also in the second nostril. The patients are then examined by TCD.
Trial: NCT01433263
Drug: BYM338 active drug
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01504334
Drug: Pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pirfenidone（200mg）tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week.
Trial: NCT01124877
Drug: ziprasidone oral capsules
RxNorm normalized name: ziprasidone Oral Capsule
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength will be provided. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing \<45 kg, the doses will range from 20 mg BID to 40 mg BID.
Trial: NCT00065806
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants weighing more 50 kg will receive 10 mg of atorvastatin po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
Trial: NCT00065806
Drug: Placebo atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants weighing more 50 kg will receive 10 mg of placebo po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
Trial: NCT04698525
Drug: Valproate Sodium
RxNorm normalized name: Valproate Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison between two actives
Trial: NCT04698525
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Memantine
Trial: NCT00581867
Drug: Insulin Aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 40IU insulin aspart applied intranasally
Trial: NCT00832494
Drug: DMXAA in combination with carboplatin and paclitaxel
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered every 21 days
Trial: NCT01929668
Drug: polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00940485
Drug: entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5mg po daily for 8 weeks
Trial: NCT00178945
Drug: Botulinum Toxin Type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Trial: NCT00940485
Drug: entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5mg po daily for 48 weeks
Trial: NCT00940485
Drug: peginterferon alfa-2a [Pegasys]
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180 micrograms sc/week for 48 weeks
Trial: NCT02459275
Drug: Metoclopramide
RxNorm normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10mg Intravenous (IV) every 6 hours (q6h) or 5mg IV q6h for renal failure will be started empirically concomitant with EN initiation. Gastric Residual Volume (GRV) will be checked every 4 hours and will be reinfused to the patient each time it is checked.
Trial: NCT01633944
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine HCl Buccal Film at doses ranging from 75-600 mcg twice daily
Trial: NCT04347486
Drug: Sugammadex Injection 2mg/kg
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous injection of 2mg/kg of sugammadex sodium on reappearance of T2
Trial: NCT02717130
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01767272
Drug: fexofenadine
RxNorm normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fexofenadine brand name
Trial: NCT02270255
Drug: 0.75% Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 ml of 0.75% Ropivacaine
Trial: NCT04347486
Drug: Sugammadex Injection 4mg/kg
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous injection of 4mg/kg of sugammadex sodium on reappearance of T2
Trial: NCT04347486
Drug: Sugammadex Injection 8mg/kg
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous injection of 8mg/kg of sugammadex sodium on reappearance of T2
Trial: NCT04347486
Drug: Neuromuscular reversal agent injection
RxNorm normalized name: edrophonium chloride Injectable Solution [Reversol]
DrugBank: Edrophonium (DB01010)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine
Trial: NCT02694224
Drug: vismodegib
RxNorm normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Smo inhibitor
Trial: NCT02694224
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (80 mg/m2) weekly x 12 doses followed by sequential dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide (600 mg/m2) each 2 weeks x 4 doses with granulocyte macrophage colony stimulating factors (GM-CSF) support
Trial: NCT02694224
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide each 2 weeks x 4 doses with GMCSF after Paclitaxel
Trial: NCT02836171
Drug: Apatinib Mesylate Tablets
RxNorm normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apatinib was administered in the morning after an overnight fast of at least 10 h
Trial: NCT02836171
Drug: Itraconazole Capsules
RxNorm normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rifampicin was administered in the morning 0.5 hours after breakfast
Trial: NCT00770120
Drug: everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01196767
Drug: Ropivacaine (in one arm); catheterization (in both).
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parallel study with two groups:~1. ropivacaine (2 mg.mL-1), at the rate of 4 mL.hr-1 through two subcutaneous catheters lateral to the sternum, both alimented by an elastomeric pump.~2. same protocol, with normal saline instead of ropivacaine.
Trial: NCT00225706
Drug: Caldolor
RxNorm normalized name: Caldolor
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01636895
Drug: Efficacy of suphladoxine/pyrimethamine as IPTp
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 tablets (single dose)given twice during pregnancy one month apart after quickening
Trial: NCT01636895
Drug: Efficacy of suphladoxine/pyrimethamine as IPTp
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 courses of 3 tablets of 500 mg N1-(5,6-dimethoxy-4-pyrimidinyl) sulfanilamide (sulfadoxine) and 25 mg 2,4-diamino-5-(p-chlorophenyl)-6-ethylpyrimidine (pyrimethamine)administered (at least 1 month apart) as DOTs to pregnant mother after quickening
Trial: NCT00164450
Drug: Rifapentine + isoniazid once weekly for 3 months
RxNorm normalized name: Rifapentine
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03912233
Drug: VX-121
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration.
Trial: NCT03912233
Drug: TEZ
RxNorm normalized name: Otezla
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TEZ tablet for oral administration.
Trial: NCT03912233
Drug: VX-561
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration.
Trial: NCT03912233
Drug: IVA
RxNorm normalized name: Viva
DrugBank: Adenosine (DB00640)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration.
Trial: NCT00020111
Drug: arsenic trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04605575
Drug: Pyrotinib 320mg + Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pyrotinib 320mg tablets administered daily by mouth, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
Trial: NCT04605575
Drug: Pyrotinib 400mg + Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pyrotinib 400mg tablets administered daily by mouth, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
Trial: NCT04605575
Drug: Pyrotinib plus Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pyrotinib administered daily by mouth（MTD）, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle, or vinorelbine(iv) 25 mg/m2 on day 1 and day 8 of 21 day cycle. Treatments will lasts until disease progression (as assessed by the investigator) or unmanageable toxicity.
Trial: NCT02840331
Drug: St. John's Wort
RxNorm normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses (900 milligram) 2-4 hours before laparoscopy
Trial: NCT01451619
Drug: Laropiprant
RxNorm normalized name: laropiprant
DrugBank: Laropiprant (DB11629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 100-mg tablet orally once daily for 4 weeks
Trial: NCT01451619
Drug: Placebo for Laropiprant
DrugBank: Laropiprant (DB11629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet orally once daily for 4 weeks
Trial: NCT02673333
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02727881
Drug: Squalamine lactate ophthalmic solution, 0.2%
DrugBank: Squalamine (DB06461)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Squalamine lactate ophthalmic solution, 0.2%
Trial: NCT02727881
Drug: ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ranibizumab
Trial: NCT04134650
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 1700mg daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
Trial: NCT00175903
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.
Trial: NCT00175903
Drug: Carbamazepine Controlled Release (CBZ-CR)
RxNorm normalized name: carbamazepine Extended Release Oral Capsule
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily dose of 600-1600 mg CR oral tablets, 200 mg and 400 mg twice daily.
Trial: NCT00006475
Drug: imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00343317
Drug: Intrapartum Cefoxitin (2g) vs. placebo
DrugBank: Cefoxitin (DB01331)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03595371
Drug: dapansutrile
RxNorm normalized name: Dapansutrile
DrugBank: Dapansutrile (DB16130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg dapansutrile administered twice daily (with a potential to increase the dosage to 2 g dapansutrile daily) for a duration of up to 14 consecutive days.
Trial: NCT01509625
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: It is an observacional retrospective study to asses the results of the administration of fulvestrant in the routine clinical practice.
Trial: NCT00501228
Drug: Filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mg/kg ID Once Daily x 1 Week
Trial: NCT03012984
Drug: Dexmedetomidine supplemented morphine analgesia
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.
Trial: NCT03012984
Drug: Morphine analgesia
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml) diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.
Trial: NCT01544179
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Investigational Drug
Trial: NCT01544179
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Chemotherapy (concomitant therapy)
Trial: NCT01544179
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy (concomitant therapy)
Trial: NCT00001705
Drug: GP100 peptide
RxNorm normalized name: Gp100:280-288(288V) peptide
DrugBank: Ovemotide (DB19156)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001705
Drug: IL-2
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00422552
Drug: Indacaterol (QAB149)
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02184832
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2 doses of 500 mg metformin given approximately 12 hrs apart
Trial: NCT04453384
Drug: XAV-19
RxNorm normalized name: XAV-19
DrugBank: XAV-19 (DB15895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1
Trial: NCT02483234
Drug: secukinumab
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00622427
Drug: Ramelteon
RxNorm normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 mg tablets every night for 2 weeks
Trial: NCT01226771
Drug: Ribavirin loading dose given
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PEG-IFN α-2a 180 μg/week plus loading (≥26 mg/kg/day for 2 weeks followed by ≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 4 weeks of therapy) dosing of ribavirin and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
Trial: NCT01226771
Drug: Priming dose of ribavirin given
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard-of-care dosing of ribavirin (≥13 mg/kg/day) without PEG-IFN for 4 weeks followed by 24-48 additional weeks of PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 28 days after the initiation of ribavirin) dosing of ribavirin and response guided treatment duration (RVR 28 weeks, non-RVR 52 weeks, pEVR consider 76 weeks), follow-up period 24 weeks
Trial: NCT01560624
Drug: Treprostinil Diolamine
RxNorm normalized name: treprostinil diolamine
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Active
Trial: NCT03863366
Drug: Prucalopride
RxNorm normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1mg prucalopride tablet, encapsulated in white capsule
Trial: NCT01226771
Drug: Group C (Standard-of-Care)
RxNorm normalized name: meningococcal group C polysaccharide
DrugBank: Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen (DB10799)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day without any measurement of ribavirin concentration) and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
Trial: NCT01797536
Drug: Elbasvir
RxNorm normalized name: Elbasvir
DrugBank: Elbasvir (DB11574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01085201
Drug: Lexiscan
RxNorm normalized name: Lexiscan
DrugBank: Regadenoson (DB06213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given as an infusion
Trial: NCT00028886
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes